trending Market Intelligence /marketintelligence/en/news-insights/trending/LOi_sceSrvA2rFe34rhqJw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aduro Biotech plans to lay off 51 employees in restructuring

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Aduro Biotech plans to lay off 51 employees in restructuring

Aduro BioTech Inc. said it plans to lay off 51 employees — or about 59% of its workforce — as part of a corporate restructuring.

The Berkeley, Calif.-based biopharmaceutical company also said it plans to minimize its corporate facilities footprint and shut down its European headquarters in Oss, The Netherlands, by the end of the third quarter.

Aduro said the restructuring is expected to extend the company's operating capital.

The company said the planned changes were determined following an analysis of its product candidates targeting the intracellular stimulator of interferon genes, or STING, and a proliferation-inducing ligand — both proteins found in the human body. STING can influence the immune response associated with various autoimmune diseases, a condition where the body's immune system attacks healthy tissue.

The company also conducted an analysis of its cGAS-STING collaboration with Eli Lilly and Co.

"We are creating a more streamlined organization by focusing on generating clinical data and identifying candidates for the cGAS program to bring forward into development," the company said in a news release.